Workflow
Nanjing Medlander Medical Technology (688273)
icon
Search documents
麦澜德(688273) - 南京麦澜德医疗科技股份有限公司2024年年度股东大会会议资料
2025-05-08 09:30
南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 证券代码:688273 证券简称:麦澜德 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 2025 年 5 月 | | | 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议资料 南京麦澜德医疗科技股份有限公司 2024 年年度股东大会会议须知 为维护全体股东的合法权益,确保南京麦澜德医疗科技股份有限公司(以下 简称"公司")股东大会顺利进行,根据《中华人民共和国证券法》《中华人民 共和国公司法》等法律法规及《南京麦澜德医疗科技股份有限公司章程》和公司 《股东大会议事规则》的相关规定,制定以下会议须知,请出席股东大会的全体 人员严格遵守。 一、全体参会人员应以维护全体股东的合法权益、保障会议的正常秩序和议 事效率为原则,自觉履行法定义务。 二、为保证股东大会的严肃性和正常秩序,除出席会议的股东(含股东代理 人,下同)、董事、监事、高级管理人员、公司聘请的律师及公司董事会要求的 人员以外,公司有权依法拒绝其他人士入场。为确认出席股东大会的股东或其他 出席者的出席资格,会议工作人员将对出席会议者的身份进行必要的核对工作, ...
麦澜德收盘上涨2.78%,滚动市盈率27.81倍,总市值29.24亿元
Sou Hu Cai Jing· 2025-05-06 13:02
Core Insights - The company, 麦澜德, closed at 29.24 yuan on May 6, with a 2.78% increase, and a rolling PE ratio of 27.81, marking a new low in 21 days, with a total market capitalization of 2.924 billion yuan [1][2] - In the medical device industry, the average PE ratio is 48.90, with a median of 36.41, placing 麦澜德 at the 64th position [1][2] - As of March 31, 2025, 麦澜德 had 4,927 shareholders, an increase of 433, with an average holding value of 352,800 yuan and an average holding of 27,600 shares [1] Company Overview - 麦澜德 specializes in the research, production, sales, and services of products related to pelvic floor and obstetric rehabilitation, focusing on female pelvic floor and obstetric rehabilitation [1] - The main products include pelvic floor and obstetric rehabilitation products, reproductive rehabilitation products, sports rehabilitation products, consumables, and information technology products [1] - 麦澜德 has been recognized as a "national manufacturing single champion" by the Ministry of Industry and Information Technology, reflecting its specialization, innovation capability, management level, market competitiveness, and social benefits in the field of pelvic floor and obstetric rehabilitation [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 118 million yuan, a year-on-year increase of 13.36%, and a net profit of 39.86 million yuan, up 9.85%, with a gross profit margin of 70.85% [2] - The company's PE ratio (TTM) is 27.81, while the industry average is 48.90, indicating a lower valuation compared to peers [2]
麦澜德(688273) - 关于第二期以集中竞价交易方式回购公司股份的进展公告
2025-05-06 09:46
证券代码:688273 证券简称:麦澜德 公告编号:2025-016 南京麦澜德医疗科技股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 案之日起 12 个月内。具体内容详见公司于 2024 年 7 月 2 日在上海证券交易所网 站(www.sse.com.cn)披露的《关于以集中竞价交易方式回购股份的回购报告书》 (公告编号:2024-041)。 公司 2024 年半年度权益分派实施后,公司以集中竞价交易方式回购股份价格 上限由不超过人民币 32.00 元/股(含)调整为不超过人民币 31.61 元/股(含)。具 体内容详见公司于 2024 年 10 月 12 日在上海证券交易所网站(www.sse.com.cn) 披露的《关于 2024 年半年度权益分派实施后调整回购价格上限的公告》(公告编 号:2024-061)。 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定,公司应在每个月 ...
麦澜德:生殖康复表现亮眼,多品类蓄力,未来可期-20250428
Xinda Securities· 2025-04-28 08:23
Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the analysis suggests a positive outlook based on revenue growth and business performance [1][2]. Core Insights - The company achieved a revenue of 425 million yuan in 2024, representing a year-over-year increase of 24.57%, with a net profit of 102 million yuan, up 13.10% year-over-year [1][2]. - The reproductive rehabilitation segment showed exceptional growth, with revenue reaching 110 million yuan in 2024, a significant increase of 126.56% year-over-year, driven by product upgrades and market expansion [2]. - The company is focusing on new product promotions, which may temporarily pressure gross margins, but the diverse product pipeline is expected to drive future growth [2]. Financial Summary - Total revenue for 2024 was 425 million yuan, with a projected growth rate of 17.0% for 2025, reaching 497 million yuan [3]. - The gross margin for the main business in 2024 was 72.25%, a decrease of 2.40 percentage points year-over-year [2]. - The company forecasts net profits of 136 million yuan in 2025, reflecting a year-over-year growth of 33.4% [3]. Business Performance - The company has strengthened its competitive position in the pelvic rehabilitation field, achieving revenue of 167 million yuan in this segment, a year-over-year increase of 3.02% [2]. - The sports rehabilitation segment saw a revenue increase of 40.76%, reaching 18.06 million yuan in 2024, supported by the sales growth of magnetic series products [2]. - The company is investing in R&D to develop innovative products, including a new generation of ultrasound diagnostic systems and radar magnetic stimulators, which are expected to enhance its market position [2].
麦澜德(688273):生殖康复表现亮眼,多品类蓄力,未来可期
Xinda Securities· 2025-04-28 08:05
Investment Rating - The report assigns a "Buy" rating for the company 麦澜德 (688273) based on its strong performance and growth potential [1]. Core Views - The company achieved a revenue of 425 million yuan in 2024, representing a year-over-year growth of 24.57%, with a net profit of 102 million yuan, up 13.10% year-over-year [1][2]. - The reproductive rehabilitation segment showed exceptional growth, with revenue reaching 110 million yuan in 2024, a significant increase of 126.56% year-over-year, driven by product upgrades and market expansion [2]. - The company is focusing on new product promotion, which has temporarily pressured gross margins, but a strong pipeline of innovative products is expected to drive future growth [2]. Financial Summary - The company’s total revenue is projected to grow from 497 million yuan in 2025 to 693 million yuan in 2027, with year-over-year growth rates of 17.0%, 17.7%, and 18.5% respectively [3]. - The net profit attributable to the parent company is expected to increase from 136 million yuan in 2025 to 201 million yuan in 2027, with growth rates of 33.4%, 22.0%, and 21.4% [3]. - The gross margin for the main business in 2024 was 72.25%, slightly down by 2.40 percentage points year-over-year, primarily due to new product promotions [2][3].
麦澜德(688273):耗材业务快速增长,积极布局潜力赛道
Hua Yuan Zheng Quan· 2025-04-24 13:53
Investment Rating - The investment rating for the company is "Buy" (maintained) due to rapid growth in consumables business and proactive layout in potential sectors [5][6]. Core Views - The company is expected to achieve revenues of 5.29 billion, 6.70 billion, and 8.48 billion RMB for the years 2025, 2026, and 2027 respectively, with year-on-year growth rates of 24.51%, 26.67%, and 26.66% [6][7]. - The net profit attributable to the parent company is projected to be 1.30 billion, 1.69 billion, and 2.20 billion RMB for the same years, with growth rates of 28.31%, 29.70%, and 30.32% [6][7]. - The company maintains a leading position in the pelvic rehabilitation field and has diversified its rehabilitation product lines, supporting the "Buy" rating [6]. Financial Performance Summary - In 2024, the company achieved a revenue of 4.25 billion RMB (yoy +24.57%) and a net profit of 1.02 billion RMB (yoy +13.10%) [8]. - For Q1 2025, the company reported a revenue of 1.18 billion RMB (yoy +13.36%) and a net profit of 0.40 billion RMB (yoy +9.85%) [8]. - The company's consumables and accessories revenue reached 1.19 billion RMB in 2024, showing a year-on-year increase of 26.21% [8]. Profitability and Margins - The gross margin for the medical device business in 2024 is 74.47%, with the main business gross margin at 72.25% [8]. - The net profit margin is reported at 25.65%, reflecting a decrease due to lower gross margins and increased operating expenses [8]. Future Outlook - The company is actively exploring potential applications in cutting-edge fields such as brain-machine interfaces and AI skin health assessment, indicating a strategic focus on innovation and growth [8].
南京麦澜德医疗科技股份有限公司关于2024年度利润分配方案的公告
登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:688273 证券简称:麦澜德 公告编号:2025-008 南京麦澜德医疗科技股份有限公司 ● 如在实施权益分派的股权登记日前公司总股本扣除公司回购专用证券账户中的股份数发生变动的,拟 维持每股分配比例不变,相应调整分配总额,并将另行公告具体调整情况。 ● 公司未触及《上海证券交易所科创板股票上市规则(2024年4月修订)》(以下简称《科创板股票上 市规则》)第12.9.1条第一款第(八)项规定的可能被实施其他风险警示的情形。 一、利润分配方案内容 经中兴华会计师事务所(特殊普通合伙)审计,南京麦澜德医疗科技股份有限公司(以下简称"公司") 2024年度归属于上市公司股东的净利润为101,581,195.08元,截至2024年12月31日,母公司可供分配利 润为158,884,120.13元。经董事会决议,公司2024年度拟以实施权益分派股权登记日登记的总股本扣除 公司回购专用证券账户中的股份数为基数分配利润,本次利润分配的方案如下: 公司拟向全体股东每10股派发现金红利人民币4.00元(含税)。截至本公告披露日,公司总股本为 100,000,000 ...
麦澜德(688273) - 关于召开2024年年度股东大会的通知
2025-04-23 13:20
证券代码:688273 证券简称:麦澜德 公告编号:2025-015 南京麦澜德医疗科技股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024年年度股东大会 召开日期时间:2025 年 5 月 14 日 14 点 00 分 召开地点:南京市雨花台区凤展路 32 号 A2 栋北 公司会议室 (五) 网络投票的系统、起止日期和投票时间。 网络投票系统:上海证券交易所股东大会网络投票系统 网络投票起止时间:自2025 年 5 月 14 日 至2025 年 5 月 14 日 采用上海证券交易所网络投票系统,通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段,即 9:15-9:25,9:30-11:30,13:00-15:00;通过互联 股东大会召开日期:2025年5月14日 本次股东大会采用的网络投票系统:上海证券交易所股东大会网络投票 系统 (二) 股东大会召集人:董事会 (三) 投票方式:本次股 ...
麦澜德(688273) - 第二届监事会第十次会议决议公告
2025-04-23 13:20
证券代码:688273 证券简称:麦澜德 公告编号:2025-007 南京麦澜德医疗科技股份有限公司 第二届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 2024 年,公司监事会严格按照《公司法》等法律法规以及《公司章程》和公 司《监事会议事规则》等制度的规定,认真地履行了自身的职责,依法独立行使 职权,促进公司规范运作,积极维护公司、全体股东及员工的合法权益。监事会 对公司的财务、股东大会决议等执行情况、董事会的重大决策程序及公司经营管 理活动的合法合规性、董事及高级管理人员履行其职务情况等方面进行了监督和 检查,促进公司的健康、持续发展。 表决结果:同意 3 票、反对 0 票、弃权 0 票。 本议案尚需提交 2024 年年度股东大会审议。 (二)审议通过《关于<公司 2024 年年度报告>及摘要的议案》 监事会认为:公司 2024 年年度报告的编制和审议程序符合相关法律法规及《公 司章程》等内部规章制度的规定;公司 2024 年年度报告的内容与格式符合相关规 定,公允地反映了公司 2024 ...
麦澜德(688273) - 第二届董事会第十二次会议决议公告
2025-04-23 13:19
证券代码:688273 证券简称:麦澜德 公告编号:2025-006 南京麦澜德医疗科技股份有限公司 第二届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 南京麦澜德医疗科技股份有限公司(以下简称"公司")于 2025 年 4 月 12 日以 邮件方式发出第二届董事会第十二次会议通知(以下简称"本次会议"),本次会议 于 2025 年 4 月 22 日以现场及通讯方式召开,由董事长杨瑞嘉先生召集并主持, 本次会议应到董事 8 人,实到董事 8 人。本次会议的召集召开符合《中华人民共 和国公司法》《上海证券交易所科创板股票上市规则》等相关法律法规、规范性 文件及《南京麦澜德医疗科技股份有限公司章程》(以下简称"《公司章程》") 的有关规定,作出的决议合法、有效。 二、董事会会议审议情况 经与会董事审议表决,形成会议决议如下: (一)审议通过《关于<公司 2024 年度董事会工作报告>的议案》 公司董事会严格按照有关法律法规、规范性文件以及公司制度规定,切实履 行股东赋予的董 ...